Upgrade to SI Premium - Free Trial

Mirum Pharmaceuticals, Inc. (MIRM)

80.39 -2.71 (3.26%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/17/26)

Latest Headlines

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences October 21, 2026 4:01 PM - BizWire Mirum Pharmaceuticals (MIRM) PT Raised to $145 at TD Cowen October 21, 2026 8:12 AM - StreetInsider Form 4 Mirum Pharmaceuticals, For: Oct 16 Filed by: Howe Jolanda October 19, 2026 4:10 PM - SEC Filing Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 15, 2026 4:01 PM - BizWire Mirum Pharmaceuticals (MIRM) PT Raised to $156 at Stifel on Clinical/Regulatory Wins October 15, 2026 9:34 AM - StreetInsider Form 4 Mirum Pharmaceuticals, For: Oct 09 Filed by: Myers Robert Paul October 14, 2026 4:07 PM - SEC Filing Form 8-K Mirum Pharmaceuticals, For: Oct 12 October 13, 2026 8:09 AM - SEC Filing Mirum Pharmaceuticals (MIRM) PT Raised to $152 at Morgan Stanley October 13, 2026 5:18 AM - StreetInsider Mirum Pharmaceuticals (MIRM) PT Raised to $184 at Citi October 12, 2026 1:57 PM - StreetInsider Raymond James on Mirum Pharmaceuticals (MIRM): 'we think its ~$1B+ estimate for the Livmarli opportunity is continuing to look more and more conservative' October 12, 2026 10:43 AM - StreetInsider Mirum gains as Phase 3 LIVMARLI trial meets primary endpoint in liver disease October 12, 2026 9:42 AM - StreetInsider TD Cowen on Mirum Pharmaceuticals (MIRM): 'We continue to view shares as undervalued' October 12, 2026 9:36 AM - StreetInsider Baird on Mirum Pharmaceuticals (MIRM): 'we expect upside for the stock' October 12, 2026 9:34 AM - StreetInsider Stifel on Mirum Pharmaceuticals (MIRM): 'We think the opportunity here remains under-appreciate' October 12, 2026 9:30 AM - StreetInsider RBC Capital on Mirum (MIRM): 'we could see MIRM shares up 5–10% on the EXPAND news' October 12, 2026 9:30 AM - StreetInsider Mirum's maralixibat meets primary endpoint in rare liver disease trial October 12, 2026 8:00 AM - StreetInsider Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases October 12, 2026 8:00 AM - BizWire Mirum Pharmaceuticals to release Phase 3 maralixibat study results October 11, 2026 5:00 PM - StreetInsider Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases October 11, 2026 5:00 PM - BizWire Mirum Pharmaceuticals (MIRM) PT Raised to $155 at RBC Capital October 8, 2026 8:27 AM - StreetInsider Form 4 Mirum Pharmaceuticals, For: Oct 06 Filed by: Peetz Christopher October 6, 2026 8:38 PM - SEC Filing Mirum Pharmaceuticals (MIRM) PT Raised to $130 at Baird September 29, 2026 7:18 AM - StreetInsider Mirum Pharmaceuticals (MIRM) PT Raised to $195 at H.C. Wainwright September 29, 2026 6:46 AM - StreetInsider Mirum Pharmaceuticals (MIRM) PT Raised to $144 at Citizens September 28, 2026 2:02 PM - StreetInsider Stifel Reiterates Buy Rating on Mirum Pharmaceuticals (MIRM) September 28, 2026 9:33 AM - StreetInsider Form 8-K Mirum Pharmaceuticals, For: Sep 25 September 28, 2026 8:03 AM - SEC Filing Mirum's brelovitug meets Phase 3 primary endpoint in hepatitis delta trial September 28, 2026 8:00 AM - StreetInsider Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus September 28, 2026 8:00 AM - BizWire Mirum Pharmaceuticals to release Phase 3 hepatitis delta trial data September 27, 2026 5:00 PM - StreetInsider Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 September 27, 2026 5:00 PM - BizWire FDA approves Atebrioz for rare bone-forming disease in patients 12 and up September 25, 2026 7:00 PM - StreetInsider Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva September 25, 2026 7:00 PM - BizWire Form 3 Mirum Pharmaceuticals, For: Sep 21 Filed by: Myers Robert Paul September 22, 2026 9:51 PM - SEC Filing Form 144 Mirum Pharmaceuticals, Filed by: BJERKHOLT ERIC September 15, 2026 4:19 PM - SEC Filing Form 4 Mirum Pharmaceuticals, For: Sep 11 Filed by: BJERKHOLT ERIC September 15, 2026 4:10 PM - SEC Filing Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 14, 2026 4:01 PM - BizWire Citizens Reiterates Market Outperform Rating on Mirum Pharmaceuticals (MIRM) September 14, 2026 9:43 AM - StreetInsider Mirum Pharmaceuticals (MIRM) Reiterated at Market Outperform by Citizens August 27, 2026 4:29 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Mirum Pharmaceuticals (MIRM) August 20, 2026 6:53 AM - StreetInsider Form 4 Mirum Pharmaceuticals, For: Aug 18 Filed by: Howe Jolanda August 19, 2026 6:20 PM - SEC Filing Form 144 Mirum Pharmaceuticals, Filed by: Howe Jolanda August 18, 2026 5:25 PM - SEC Filing Form SCHEDULE 13G/A Mirum Pharmaceuticals, Filed by: Janus Henderson Group Ltd. August 13, 2026 12:48 PM - SEC Filing Form 4 Mirum Pharmaceuticals, For: Aug 11 Filed by: BJERKHOLT ERIC August 12, 2026 5:15 PM - SEC Filing Form 4 Mirum Pharmaceuticals, For: Aug 10 Filed by: Peetz Christopher August 11, 2026 5:42 PM - SEC Filing Form 144 Mirum Pharmaceuticals, Filed by: BJERKHOLT ERIC August 11, 2026 4:13 PM - SEC Filing Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 11, 2026 4:01 PM - BizWire Form 144 Mirum Pharmaceuticals, Filed by: Peetz Christopher August 10, 2026 4:19 PM - SEC Filing Form SCHEDULE 13G Mirum Pharmaceuticals, Filed by: FMR LLC August 6, 2026 10:36 AM - SEC Filing Mirum Pharmaceuticals (MIRM) PT Lowered to $137 at Morgan Stanley August 6, 2026 8:52 AM - StreetInsider Mirum Pharmaceuticals (MIRM) PT Lowered to $123 at Baird August 6, 2026 8:30 AM - StreetInsider Mirum Pharmaceuticals (MIRM) PT Lowered to $140 at TD Cowen August 6, 2026 8:08 AM - StreetInsider Mirum Pharmaceuticals (MIRM) PT Lowered to $140 at H.C. Wainwright August 6, 2026 6:54 AM - StreetInsider Mirum Pharmaceuticals (MIRM) PT Lowered to $135 at RBC Capital August 6, 2026 6:52 AM - StreetInsider Mirum Pharmaceuticals (MIRM) PT Lowered to $137 at Citizens August 6, 2026 6:31 AM - StreetInsider Mirum Pharmaceuticals, Inc. (MIRM) Misses Q2 EPS by 32c ; Offers Guidance August 6, 2026 12:59 AM - StreetInsider Form 4 Mirum Pharmaceuticals, For: Aug 03 Filed by: Howe Jolanda August 5, 2026 4:29 PM - SEC Filing Form 10-Q Mirum Pharmaceuticals, For: Jun 30 August 5, 2026 4:09 PM - SEC Filing Form 8-K Mirum Pharmaceuticals, For: Aug 05 August 5, 2026 4:03 PM - SEC Filing Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update August 5, 2026 4:01 PM - BizWire Form 144 Mirum Pharmaceuticals, Filed by: Howe Jolanda August 3, 2026 4:08 PM - SEC Filing Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 July 29, 2026 4:01 PM - BizWire Full Article List